

Composite type-2 biomarker strategy versus a symptom
corticosteroid dose in patients with severe asthma: a m
group, randomised controlled trial

Lancet Respiratory Medicine, the
9, 57-68

DOI: [10.1016/s2213-2600\(20\)30397-0](https://doi.org/10.1016/s2213-2600(20)30397-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. <i>Thorax</i> , 2021, 76, 220-227.	5.6	83
2	More options for managing severe asthma in adults. <i>Lancet Respiratory Medicine</i> , 2021, 9, 3-5.	10.7	7
3	Balancing the needs of the many and the few: where next for adult asthma guidelines?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 786-794.	10.7	18
4	A Proposed Revision of the Stepwise Treatment Algorithm in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 100-103.	5.6	2
5	Using biomarkers to adjust corticosteroid dose in patients with severe asthma. <i>Breathe</i> , 2021, 17, 200324.	1.3	0
6	Granulocytic Airway Inflammation and Clinical Asthma Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 797-799.	5.6	3
7	Managing Corticosteroid-Related Comorbidities in Severe Asthma. <i>Chest</i> , 2021, 160, 1614-1623.	0.8	8
8	Medical algorithms: Approach to adult asthma exacerbations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3556-3559.	5.7	3
9	Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1159-1168.	2.5	9
10	Contemporary Concise Review 2020: Asthma. <i>Respirology</i> , 2021, 26, 804-811.	2.3	5
11	A Survey on the Management of Children with Asthma in Primary Care Setting in Italy. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2021, 34, 39-42.	0.8	6
12	Treatable Traits in Asthma and COPD. <i>Archivos De Bronconeumologia</i> , 2022, 58, 583-585.	0.8	10
13	Management Strategies to Reduce Exacerbations in non-T2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2588-2597.	3.8	10
14	Prevention and Treatment of Asthma Exacerbations in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2578-2586.	3.8	13
15	Biomarkers of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.9	9
16	Workup of Severe Asthma. <i>Chest</i> , 2021, 160, 2019-2029.	0.8	18
17	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4353-4370.	3.8	12
18	Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 283-291.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.8	109
20	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 731-734.	5.6	40
21	Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. <i>Respirology</i> , 2021, 26, 1112-1130.	2.3	35
22	Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 407-414.	3.2	11
23	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.	6.7	8
24	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. <i>Respiratory Medicine</i> , 2021, 187, 106572.	2.9	29
25	Biomarkers in Asthma. , 2022, , 342-351.		1
26	Asthma bronchiale. <i>Karger Kompass Pneumologie</i> , 2021, 9, 163-165.	0.0	0
27	Using Fractional Exhaled Nitric Oxide Measurement in Clinical Asthma Management. <i>Chest</i> , 2022, 161, 906-917.	0.8	23
28	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	6.7	10
29	Blood eosinophils in managing preschool wheeze: Lessons learnt from a proof-of-concept trial. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	7
30	Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life. <i>Biomedicines</i> , 2021, 9, 1684.	3.2	33
31	Mechanisms of Mast Cell Activation in Severe Asthma: Beyond IgE. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 375-377.	5.6	2
32	Current unmet needs and potential solutions to uncontrolled asthma. <i>European Respiratory Review</i> , 2022, 31, 210176.	7.1	24
33	Differential diagnosis of pulmonary eosinophilia. , 2022, , 19-36.		3
34	Eosinophilic asthma. , 2022, , 73-99.		2
35	Biomarkers of eosinophilic inflammation. , 2022, , 37-50.		2
36	Considering biomarkers in asthma disease severity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 480-487.	2.9	12

#	ARTICLE	IF	CITATIONS
37	STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life. BMC Pulmonary Medicine, 2022, 22, 53.	2.0	1
38	Should we apply a treatable traits approach to asthma care?. Annals of Allergy, Asthma and Immunology, 2022, 128, 390-397.	1.0	10
39	Holy Grail: the journey towards disease modification in asthma. European Respiratory Review, 2022, 31, 210183.	7.1	15
40	Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1534-1544.e4.	3.8	21
41	FeNO in Asthma. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 635-645.	2.1	23
42	Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Annals of Allergy, Asthma and Immunology, 2022, 129, 169-180.	1.0	28
43	Novel Potential Treatable Traits in Asthma: Where is the research taking us?. , 2022, , .		0
44	Which Therapy for Non-Type(T)2/T2-Low Asthma. Journal of Personalized Medicine, 2022, 12, 10.	2.5	15
45	Kongress der European Respiratory Society (ERS): Von Alveolarproteinose bis Pertussisimpfung. , 0, , .		0
46	Disease-modifying anti-asthmatic drugs. Lancet, The, 2022, 399, 1664-1668.	13.7	42
47	T2-low: what do we know?. Annals of Allergy, Asthma and Immunology, 2022, 129, 150-159.	1.0	11
48	Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2438-2447.e9.	3.8	9
49	Exacerbation Profile and Risk Factors in a Type-2“Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 545-553.	5.6	14
50	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker“high and “low severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2974-2986.	5.7	11
51	Recent developments in the management of severe asthma. Breathe, 2022, 18, 210178.	1.3	1
52	Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT. Efficacy and Mechanism Evaluation, 2022, 9, 1-154.	0.7	1
53	Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunology and Allergy Clinics of North America, 2022, , .	1.9	0
54	An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma. European Respiratory Journal, 2022, 60, 2103205.	6.7	5

#	ARTICLE	IF	CITATIONS
55	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	5.7	7
56	Treatable traits in the NOVELTY study. <i>Respirology</i> , 2022, 27, 929-940.	2.3	29
57	What is the added value of FeNO as T2 biomarker?. <i>Frontiers in Allergy</i> , 0, 3, .	2.8	5
58	Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	2.6	3
59	Conventional Atopic Diseases. , 2022, , 117-164.		0
61	Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting Î2-agonists and corticosteroids. <i>International Journal of Medical Sciences</i> , 2022, 19, 1770-1778.	2.5	2
62	Tackling "People Remodelling"™ in Corticosteroid-dependent Asthma with Type-2 Targeting Biologics and a Formal Corticosteroid Weaning Protocol. <i>US Respiratory & Pulmonary Diseases</i> , 2022, 7, 44.	0.2	3
63	Protocol, rationale and design of the PHOLLOW cross-sectional and retrospective chart review study to assess the prevalence and characterize the patient profile, clinical features and disease burden of type-2 low severe asthma in routine care settings in Greece. <i>Pneumon</i> , 2022, 35, 1-13.	0.3	0
64	A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 1233-1242.e5.	3.8	6
66	Toward a Predict and Prevent Approach in Obstructive Airway Diseases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 704-712.	3.8	9
67	Is asthma's heterogeneity too vast to use traditional phenotyping for modern biologic therapies?. <i>Respiratory Medicine</i> , 2023, 212, 107211.	2.9	0
68	A novel assay for improved detection of sputum periostin in patients with asthma. <i>PLoS ONE</i> , 2023, 18, e0281356.	2.5	3
69	Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. <i>Lancet Respiratory Medicine</i> , 2023, 11, 591-601.	10.7	12
70	Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma. <i>Thorax</i> , 2023, 78, 868-874.	5.6	0
71	Physiology and Biomarkers for Surveillance of Occupational Lung Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	2.1	1
72	Effectiveness of FeNO-guided treatment in adult asthma patients: A systematic review and meta-analysis. <i>Clinical and Experimental Allergy</i> , 2023, 53, 798-808.	2.9	2
73	Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 152, 876-886.	2.9	0
74	Basic clinical management of preschool wheeze. <i>Pediatric Allergy and Immunology</i> , 2023, 34, .	2.6	1

#	ARTICLE	IF	CITATIONS
75	Clinical Trial Design Innovations for Precision Medicine in Asthma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 395-412.	1.6	1
76	Approaches to Management of Asthma: Guidelines for Stepped Care and Self-Monitoring. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 355-375.	1.6	0
77	EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients. <i>Respiratory Medicine</i> , 2023, 218, 107361.	2.9	0
78	Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review. <i>World Journal of Diabetes</i> , 0, 14, 1202-1211.	3.5	1
79	Eosinophils“from cradle to grave. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 3077-3102.	5.7	5
80	Asthma and COPD: A Focus on Î²-Agonists “ Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	1.8	0
81	Bringing the treatable traits approach to primary care asthma management. <i>Frontiers in Allergy</i> , 0, 4, .	2.8	1
82	Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. <i>Respiratory Medicine</i> , 2023, 218, 107414.	2.9	4
83	Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype “ a randomized controlled trial study protocol. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	1
84	Promising treatment biomarkers in asthma. <i>Frontiers in Drug Safety and Regulation</i> , 0, 3, .	1.8	0
85	Pulmonology for the rhinologist. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 0, , .	1.8	0
86	Fractional exhaled nitric oxide (FeNO): the future of asthma care?. <i>British Journal of General Practice</i> , 2023, 73, 565-568.	1.4	0
87	Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2024, 12, 809-823.	3.8	1
88	New targets for type 2-low asthma. <i>Korean Journal of Internal Medicine</i> , 2024, 39, 215-227.	1.7	0